These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17960017)

  • 1. Clinical decisions. Management of stable coronary disease.
    Yusuf S; Fallen E; Harrington RA; Guyton RA
    N Engl J Med; 2007 Oct; 357(17):1762-6. PubMed ID: 17960017
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
    Soares PR; Hueb WA; Lemos PA; Lopes N; Martinez EE; Cesar LA; Oliveira SA; Ramires JA
    Circulation; 2006 Jul; 114(1 Suppl):I420-4. PubMed ID: 16820611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular events after percutaneous coronary intervention.
    Herrmann HC
    N Engl J Med; 2004 Jun; 350(26):2708-10. PubMed ID: 15215488
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary prevention of ischaemic cardiac events.
    Gami A
    Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
    [No Abstract]   [Full Text] [Related]  

  • 5. Stents versus bypass grafting for left main coronary artery disease.
    Tayek JA
    N Engl J Med; 2008 Jul; 359(4):424; author reply 425. PubMed ID: 18655244
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M; Malmberg K; Ohrvik J; Rydén L;
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy.
    Jaumdally R; Lip GY; Varma C
    Int J Clin Pract; 2005 Sep; 59(9):1070-81. PubMed ID: 16115184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?].
    Kolenda KD
    Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of stable & unstable angina in elderly patients.
    Brann WM; Tresch DD
    Compr Ther; 1997 Jan; 23(1):49-56. PubMed ID: 9067083
    [No Abstract]   [Full Text] [Related]  

  • 10. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
    Fox DJ; Kibiro M; Eichhöfer J; Curzen NP
    Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy versus percutaneous coronary intervention for patients with stable coronary artery disease.
    Arbab-Zadeh A
    J Am Coll Cardiol; 2009 Feb; 53(6):528-9; author reply 529. PubMed ID: 19195616
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
    Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiovascular events in diabetes.
    Malcolm J; Meggison H; Sigal R
    Clin Evid; 2003 Dec; (10):690-714. PubMed ID: 15555116
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 15. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
    Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
    Eisenberg MJ; Okrainec K; Lefkovits J; Goudreau E; Deligonul U; Mak KH; Duerr R; Tsang J; Huynh T; Sedlis S; Brown DL; Brieger D; Pilote L;
    Can J Cardiol; 2003 Aug; 19(9):1009-15. PubMed ID: 12915928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery.
    Karki DB; Neopane A
    Kathmandu Univ Med J (KUMJ); 2003; 1(4):284-7. PubMed ID: 16388272
    [No Abstract]   [Full Text] [Related]  

  • 18. [Management of stable coronary artery disease].
    Jacobshagen C; Hasenfuss G
    MMW Fortschr Med; 2009 Nov; 151(47):45-9; quiz 50. PubMed ID: 20037979
    [No Abstract]   [Full Text] [Related]  

  • 19. Today's guidance.
    Mansfield M
    Diabet Med; 2004 Sep; 21 Suppl 4():5-8. PubMed ID: 15315517
    [No Abstract]   [Full Text] [Related]  

  • 20. [Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
    Bory M
    Arch Mal Coeur Vaiss; 2000 Dec; 93 Spec No 4():45-50. PubMed ID: 11296462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.